Vedanta Oil and Gas Regulatory Approval

Employee Stock Options

Vedanta Oil and Gas Employee Stock Options

Vedanta Oil and Gas's performance-based ESOS 2016 grants vested for 55,16,340 options, priced at par. Exercise is open for 8 months, with exercise money not yet determined.

Execution

8 months from vesting date (November 04, 2026), or such other period as approved by the NRC

Earnings Call

Vedanta Oil and Gas Investor Presentation: Key Takeaways

Q2FY27 revenue ₹2,486 Cr (+7% YoY), EBITDA ₹1,393 Cr (+34%, 56% margin), PAT ₹746 Cr. Price-led growth; gross production down 19% YoY.

Management Change

Vedanta Oil and Gas Management Change

Vedanta Oil and Gas's Company Secretary Shivangi Dhanuka resigned effective 31 October 2026. Rupesh Kumar succeeds her as KMP from 1 November 2026.

Financial Results

Vedanta Oil and Gas Q2 FY27 Results: Turns Profitable, Net Profit ₹746 Cr

Vedanta Oil and Gas Ltd reported revenue from operations of ₹2,488 Cr (+6.2% YoY) and net profit of ₹746 Cr for Q2 FY27.

Key figure

Net profit ₹746 Cr

Annual General Meeting

Vedanta Oil and Gas Annual General Meeting

Vedanta Oil and Gas shareholders approved its 2026 ESOP and share purchase plans via postal ballot. Votes in favour ranged from about 97% to 99%.

Board Meeting Date

Vedanta Oil and Gas Board Meeting Date

Vedanta Oil and Gas Ltd schedules a board meeting for October 29, 2026, to consider unaudited financial results for the quarter ended September 30, 2026.

Regulatory ApprovalDr. Reddy's Laboratories Ltd DRREDDYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.

Regulatory ApprovalEmmbi Industries Ltd EMMBIAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Emmbi Industries Regulatory Approval

SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.

Regulatory ApprovalBliss GVS Pharma Ltd BLISSGVSAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Bliss GVS Pharma Regulatory Approval

Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.

Regulatory ApprovalJohn Cockerill India Ltd COCKERILLAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

John Cockerill India Regulatory Approval

John Cockerill India received Reserve Bank of India approval for acquiring shares of John Cockerill Metals International SA. This allows the company to proceed with the share-swap acquisition.

Regulatory ApprovalGland Pharma Ltd GLANDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Gland Pharma Regulatory Approval

Gland Pharma received USFDA approval for Methylprednisolone Acetate Injectable Suspension USP in multiple vial formats. The product is bioequivalent to Pfizer's Depo-Medrol in a ~$214M US market.